Development of a National Indication Protocol for Proton Therapy in Patients With Seminoma Testis to Reduce the Risk on Subsequent Primary Cancers
We defined an NIPP for the selection of STPs for PT in the Netherlands, aimed to reduce the risk of SPC. According to this NIPP, about 75% of these patients qualify for PT. Further studies are required to allow inclusion of nononcological late effects as selection criteria in the NIPP.
Authors
- Johannes A. Langendijk (ORCID: https://orcid.org/0000-0003-1083-372X)
- Mirko Unipan (ORCID: https://orcid.org/0000-0003-4965-290X)
- Erik C. Schimmel
- Charlotte L. Brouwer (ORCID: https://orcid.org/0000-0002-2349-7369)
- Martine Franckena (ORCID: https://orcid.org/0000-0001-5138-4348)
- Marianne A. A. de Jong
- P. Bakker
- Yvonne L.B. Klaver
- Shafak Al Uwini
- Peter F. Sinnige (ORCID: https://orcid.org/0000-0002-4132-9174)
- Robert Jan Smeenk (ORCID: https://orcid.org/0000-0001-5492-9307)
- Tom C.G. Budiharto
- Maarten L.P. Dirkx
- Wilma D Heemsbergen
- Rob P. Coppes
- Nienke Kuijsters
- Ben Vanneste
- Ewoud Schuit
- Ada Oele
- Steven JM Habraken (ORCID: https://orcid.org/0009-0002-1168-3479)
- L. J. Boersma
Institutions
- University Medical Center Groningen (NL)
- Radboud University Nijmegen (NL)
- Leiden University Medical Center (NL)
- Catharina Ziekenhuis (NL)
- Erasmus MC (NL)
- University Medical Center Utrecht (NL)
- Instituut Verbeeten (NL)
- Radiotherapiegroep (NL)
- Erasmus MC Cancer Institute (NL)
- Radiotherapeutisch Instituut Friesland (NL)
- Maastro Clinic (NL)
Publication Details
- Journal
- International Journal of Radiation Oncology*Biology*Physics
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.ijrobp.2026.02.207
- Primary Topic
- Testicular diseases and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00